Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Public ClinicalTrials.gov record NCT04728893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
Study identification
- NCT ID
- NCT04728893
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 490 participants
Conditions and interventions
Conditions
Interventions
- Nemtabrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2021
- Primary completion
- Jan 3, 2029
- Completion
- Jan 3, 2029
- Last update posted
- May 3, 2026
2021 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group ( Site 2728) | Springdale | Arkansas | 72762 | Recruiting |
| University of California San Diego Moores Cancer Center ( Site 2717) | La Jolla | California | 92093-0698 | Recruiting |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724) | Torrance | California | 90502 | Completed |
| Colorado Blood Cancer Institute ( Site 2726) | Denver | Colorado | 80218 | Recruiting |
| The University of Louisville, James Graham Brown Cancer Center ( Site 2729) | Louisville | Kentucky | 40202 | Completed |
| Mayo Clinic - Rochester ( Site 2706) | Rochester | Minnesota | 55905 | Recruiting |
| Astera Cancer Care ( Site 2732) | East Brunswick | New Jersey | 08816 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) | Hackensack | New Jersey | 07601 | Recruiting |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708) | Fargo | North Dakota | 58102 | Completed |
| UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730) | Dallas | Texas | 75390 | Recruiting |
| Medical Oncology Associates (Summit Cancer Centers) ( Site 2710) | Spokane | Washington | 99208 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04728893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04728893 live on ClinicalTrials.gov.